Experimental CAR-T therapy for lymphoma trial ends early
NCT ID NCT06248086
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new type of CAR-T cell therapy (ASP2802) for people with B-cell lymphoma that came back or stopped responding to treatment. The therapy uses a person's own immune cells, modified to better fight cancer, plus a booster protein. The study was terminated after only one participant was enrolled, so we have very limited information about its safety or effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Site AU61004
Sydney, 3065, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Engineered immune cells take aim at tough childhood leukemia
- Scientists build a biobank to crack the mystery of CAR-T cell failure
- Boosting CAR t cells: could a pill make lymphoma therapy more effective?
- Military study probes Toxins' role in lymphoma
- Off-the-Shelf immune cells take on tough lymphoma